Vanda Pharmaceuticals Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($18.0m) ($15.6m) $25.2m $115.6m $23.3m $33.2m $6.3m $2.5m ($18.9m) ($220.5m)
Depreciation $935k $1.2m $1.4m $1.4m $1.4m $1.4m $1.2m $920k $859k $1.1m
Amortization of Intangible Assets $10.9m $1.8m $1.5m $1.5m $1.5m $1.5m $1.5m $2.1m $7.3m $7.0m
Deferred Income Tax Expense (Benefit) ($104k) ($87.8m) $6.2m $6.7m $1.1m ($1.3m) ($6.5m) $81.4m
Share-based Payment Arrangement, Noncash Expense $8.5m $10.5m $11.7m $13.5m $13.4m $15.4m $16.3m $14.0m $12.4m $9.5m
Payment, Tax Withholding, Share-based Payment Arrangement $915k
Share-based Payment Arrangement, Expense $8.5m $10.5m $11.7m $13.5m $13.4m $15.4m $16.3m $14.0m $12.4m $9.5m
Income Tax Expense (Benefit) $104k $136k $138k ($86.5m) $8.3m $9.2m $5.0m $3.8m ($4.0m) $81.8m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $4.3m ($2.5m) $11.2m ($2.3m) $3.8m $2.5m $1.1m $707k $13.0m $7.5m
Increase (Decrease) in Inventories ($200k) $1.1m ($70k) $722k $2.9m $2.2m $4.5m $771k $29k $3.5m
Proceeds from Stock Options Exercised $5.3m $6.3m $6.3m $5.6m $3.5m $734k $0 $0
Debt Securities, Available-for-sale, Realized Gain (Loss) $229k $12k $0 ($655k) $0 $0
Net Cash Provided by (Used in) Operating Activities ($8.1m) ($2.0m) $30.0m $45.9m $51.8m $64.2m $32.0m $12.8m ($15.8m) ($109.4m)
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $1.4m $1.7m $368k $1.0m $1.8m $552k $679k $383k $490k $998k
Payments for (Proceeds from) Other Investing Activities ($124k)
Net Cash Provided by (Used in) Investing Activities ($10.1m) ($10.1m) ($109.7m) ($68.3m) ($41.5m) ($76.7m) $49.9m ($12.1m) ($17.4m) $94.9m
Cash flows from financing activities:
Proceeds from Issuance of Common Stock $100.9m $0 $0
Net Cash Provided by (Used in) Financing Activities $7.8m $5.3m $107.1m $6.3m $5.6m $3.5m $734k $0 ($155k) ($2.9m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5k $42k ($38k) ($1k) $53k ($91k) $265k $47k ($163k) $23k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5k $42k $27.4m ($16.1m) $16.0m ($9.0m) $82.9m $792k ($33.5m) ($17.5m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5k $42k $61.7m $45.6m $61.6m $52.6m $135.5m $136.3m $102.8m $85.3m
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net $3.6m $2.4m ($90k)